Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 25;12(11):1026-1028.
doi: 10.18632/oncotarget.27957.

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?

Leandro H Gallo

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?

Leandro H Gallo. Oncotarget. .
No abstract available

Keywords: cancer stem cells; castration-resistant; metastasis; prostate cancer; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. FGFR1 contributes to the stemness of prostate cancer cells with tumor initiating potential.
(A) Tumors usually exhibit a heterogeneous phenotype with subpopulations of cells at different clonal stages as illustrated by cells colored in green, magenta, and blue. Upregulation of FGFR1 signaling (shown in blue colored cells) leads to the activation of oncogenic MAPK, AKT, and STATs, culminating in cellular survival, proliferation, and expression of stem cell markers. Treatment with tyrosine kinase inhibitors (TKI), Dovitinib and Infigratinib (BJG398), impairs spheroid formation of prostate cancer stem cells. (B) It remains to be investigated whether FGFR1-upregulated cancer stem cells potentiate progression to metastatic and castration-resistant prostate cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cronin KA, et al.. Cancer. 2018; 124:2785–800. 10.1002/cncr.31551. - DOI - PMC - PubMed
    1. Huggins C, et al.. Cancer Res. 1941; 1:293–97.
    1. Urbanucci A, et al.. Oncogene. 2012; 31:2153–63. 10.1038/onc.2011.401. - DOI - PubMed
    1. Finones RR, et al.. PLoS One. 2013; 8:e74438. 10.1371/journal.pone.0074438. - DOI - PMC - PubMed
    1. Jiang MY, et al.. Oncotarget. 2016; 7:76159–68. 10.18632/oncotarget.12709. - DOI - PMC - PubMed